HGF and myocardial infarction: Phase II clinical trials using HGF mimetics for treating heart attack and delayed kidney graft function are currently in progress, suggesting that such an approach to DMD may well be feasible and safe.40, 41 Based on our findings, HGF/Met might be a new target for reducing inflammation, prolonging fiber integrity and delaying disease progression in dystrophic muscle.